Long-term results with custom-linked iodine-125 seeds and real-time brachytherapy in low- and intermediate-risk prostate cancer

Jose Luis Guinot, MD, PhD, Juan Casanova, MD, Victor Gonzalez-Perez, PhD, Miguel Angel Santos, MD, Victor De las Dolores, MD, Maria Isabel Tortajada, MD, Carmen Guardino, PhD, Vicente Crispin, MD, Jose Rubio-Briones, MD, Leoncio Arribas, MD, PhD

Department of Radiation Oncology, Fundacion Instituto Valenciano de Oncologia (I.V.O.) Valencia, Spain. Department of Urology, Fundacion Instituto Valenciano de Oncologia (I.V.O.) Valencia, Spain. Department of Radiation Physics, Fundacion Instituto Valenciano de Oncologia (I.V.O.) Valencia, Spain.

Abstract

Purpose: Brachytherapy (BT) with iodine-125 (125I) seeds is effective in low- and intermediate-risk prostate carcinoma, with fewer side effects compared to other techniques, but relapses increase in long-term. In the present paper, 10-year biochemical relapse-free survival (BRFS) results are presented.

Material and methods: Between 2007 and 2016, 706 patients were treated with real-time technique using Bard-ProLink™ system. 145 Gy was administered to the prostate with exclusive BT and 108 Gy after 46 Gy of external radiotherapy (EBRT). Androgen deprivation therapy was applied in 19.3% of patients.

Results: Median follow-up was 96 months (range, 24-163 months). BRFS at 5 and 10 years was 95% and 91.1%, respectively. For 480 low-risk cases, BRFS at 5 and 10 years was 95.7% and 92.7%, and for 226 intermediate-risk cases, it was 92.7% and 88%, respectively (p < 0.05). With combined treatment of EBRT + BT, 133 cases (59%) of intermediate-risk were treated without differences with exclusive BT. Gleason score 4 + 3 cases dropped to 72.8% at 10 years (p < 0.001), with androgen deprivation therapy (ADT) to 90.9% and without ADT to 66.8%; it was worse if patients had exclusive BT. 10-year BRFS for T1c was 95% compared to 84% for T2 (p < 0.001). Initial prostate specific antigen (PSA) > or < 10 showed no differences. With > 50% biopsy cores positive, it fell to 80% at 10 years (p < 0.001). In 154 patients up to 60 years of age, 10-year BRFS was 97.6%. Urinary complications appeared in 16.9% of cases in exclusive BT vs. 26.1% in EBRT + BT. Grade 2+ urinary late complications were observed in 19.1% and grade 3+ in 5.8% of patients. Rectal toxicity was 4% (2.5% in BT alone and 10.1% in RT + BT), while G3+ was seen in 0.1%.

Conclusions: Real-time BT with custom-linked 125I seeds is a very effective long-term treatment in low- and intermediate-risk prostate carcinoma. With Gleason score 4 + 3 or > 50% biopsy cores positive, we recommend combined treatment with additional ADT for 6 months.

Key words: prostate, brachytherapy, 125I seeds, low-risk, intermediate-risk, long-term, custom-linked seeds.
According to the European Urology Association (EUA), the EORTC and the American Urology Association (AUA), and National Comprehensive Cancer Network (NCCN) [1], tumors are divided into three risk groups for a relapse: low-risk, when PSA is < 10 ng/ml, tumor located in the prostate T1-T2a, and histological classification with a Gleason score ≤ 6; intermediate-risk, means having an extensive intra-capsular tumor that is palpable or visible by image (T2b-c) or Gleason 7, or PSA between 10 and 20 ng/ml; high-risk, when the tumor ruptures the capsule (T3) or PSA is > 20 ng/ml, or Gleason score ranges between 8 and 10. There are several classifications with modifications. According to the Seattle classification and the Mount Sinai Hospital in New York, the presence of two intermediate factors is regarded as high-risk. The latter also considers a T2b-c high-risk, as does the D’Amico classification [2], widely used by urologists.

There is a good deal of agreement with low-risk groups the D’Amico classification [2], widely used by urologists. The latter also considers a T2b-c high-risk, as does the D’Amico classification [2], widely used by urologists. There is a good deal of agreement with low-risk groups the D’Amico classification [2], widely used by urologists.

Table 1. Characteristics of the 706 patients

| Characteristics                  | Total | %   |
|----------------------------------|-------|-----|
| **Gleason score**                |       |     |
| 3 + 3                            | 571   | 80.9|
| 3 + 4                            | 94    | 13.3|
| 4 + 3                            | 41    | 5.8 |
| **T stage**                      |       |     |
| T1c                              | 480   | 68.0|
| T2a                              | 170   | 24.1|
| T2b                              | 22    | 3.1 |
| T2c                              | 34    | 4.8 |
| **PSA level (ng/ml)**            |       |     |
| < 10                             | 613   | 86.8|
| > 10-20                          | 93    | 13.2|
| **Risk group**                   |       |     |
| Low                              | 480   | 68.0|
| Intermediate                     | 226   | 32.0|
| **Biopsy cores**                 |       |     |
| ≤ 50% positive                   | 608   | 86.1|
| > 50% positive                   | 50    | 7.1 |
| Unknown                          | 48    | 6.8 |
| **Irradiation**                  |       |     |
| Exclusive BT                     | 568   | 80.5|
| EBRT + BT                        | 138   | 19.5|
| **Androgen deprivation**         |       |     |
| No                               | 570   | 80.7|
| Yes                              | 136   | 19.3|
| **Mean age (range)**             | 66 (44-81) |     |
| Seeds (mean)                     | 57 (20-89)    |     |
| mCi total (mean)                 | 26.58 (7.6-56) |     |
| Prostate volume (cc)             |       |     |
| Before hormone                   | 32 (11-91) |     |
| Before implant                   | 30 (6.9-73)  |     |

**EBRT – external beam radiotherapy, BT – brachytherapy, mCi – miliCurie**
Long-term results with custom-linked iodine-125 seeds and real-time brachytherapy in low- and intermediate-risk prostate cancer

Treatment with bicalutamide for four weeks and luteinizing hormone-releasing hormone (LHRH) analog was administered in 19.2% of cases, some prescribed by their urologist for six months, others for three months to reduce volume of the prostate and be able to perform the implant in a more suitable way. In total, 15% of low-risk cases had androgen deprivation therapy (ADT), and 27% of intermediate-risk patients. Characteristics of the patients are shown in Table 1.

All the patients were evaluated by means of a prostate volumetry a few weeks before to know the size, shape, and feasibility of the implant, and to order the seeds with adequate activity. In some cases, multiparametric MRI was performed, but not systematically. BT implant was performed under spinal anesthesia. Ultrasound images were taken every 5 mm. Then, needles were inserted to cover periphery of the prostate, the image was recorded again, and the dosimetry was calculated. It was then decided whether it was necessary to add central needles. In the same operating room, rows of seeds and spacers were built using Bard QuickLink™ system, avoiding using loose seeds. Before concluding, the final dosimetry was evaluated to insert some seed in uncovered areas, so that good coverage and dosimetry were achieved in vast majority of cases.

Follow-up at one month and a CT scan were performed for subsequent dosimetry. PSA control started at three months, then every 4-6 months, up to 5 years, and then annually. Biochemical relapse was considered according to the Phoenix criteria, when PSA rises to nadir + 2 ng/ml. During the first two years, there were frequent cases of transient elevation; therefore, despite a criterion of relapse, no further investigations were required other than close monitoring of PSA every three months. To achieve a more homogeneous population, only patients with at least two years of follow-up were included in this study. Regarding toxicity, CTCAE v. 5.0 classification was applied [6].

For statistical analysis of data, SPSS-15 statistical program was used to determine biochemical relapse-free survival (BRFS) by means of Kaplan-Meyer actuarial method. Comparison between series was made with log-rank test, considering \( p < 0.05 \) as significant value.

Results

The median follow-up was 96 months, with a range between 24 and 163 months. BRFS at 5 and 10 years were calculated (Table 2), and for the 706 cases, it was 95% and 91.1%, respectively. For the 480 low-risk cases, BRFS was 95.7% and 92.7%, and for the 226 intermediate-risk cases, it was 92.7% and 88%, a significant difference (\( p < 0.05 \)) compared with low-risk cases (Fig. 1). With EBRT + BT combined treatment, 5 low-risk cases (due to inadequate implants) were treated without relapses, and 133 intermediate-risk cases (59%) without significant differences, with the cases of exclusive BT.

According to Gleason score, no differences between 3 + 3 and 3 + 4 were observed, but with Gleason 4 + 3, BRFS dropped to 84.7% and 72.8% at 5 and 10 years (\( p < 0.001 \)), respectively (Fig. 2). In patients receiving ADT and in those not receiving ADT, G3 + 3 and G3 + 4 were

Table 2. Biochemical relapse-free survival (BRFS) at 5 and 10 years

|                      | Patients | 5-year (%) | 10-year (%) | \( p \)-value |
|----------------------|----------|------------|-------------|--------------|
| **Total**            | 706      | 95.0       | 91.1        |              |
| **Risk group**       |          |            |             |              |
| Low                  | 480      | 95.7       | 92.7        | \( p < 0.05 \) |
| Intermediate         | 226      | 92.7       | 88.0        |              |
| **Gleason score**    |          |            |             | \( p < 0.001 \) |
| 3 + 3                | 571      | 95.7       | 92.7        |              |
| 3 + 4                | 94       | 93.4       | 89.5        |              |
| 4 + 3                | 41       | 84.7       | 72.8        |              |
| **T stage**          |          |            |             | \( p < 0.001 \) |
| T1c                  | 480      | 96.1       | 95.0        |              |
| T2                   | 226      | 92.0       | 84.0        |              |
| **PSA level (ng/ml)**|          |            |             | N.S.         |
| < 10                 | 613      | 95.0       | 91.6        |              |
| 10-20                | 93       | 93.3       | 88.9        |              |
| **Biopsy cores**     |          |            |             | \( p < 0.001 \) |
| ≤ 50% positive       | 608      | 95.7       | 92.0        |              |
| > 50% positive       | 50       | 80.0       | 80.0        |              |
| **Age (years)**      |          |            |             | 0.007        |
| < 61                 | 154      | 98.6       | 97.6        |              |
| 61-70                | 352      | 93.3       | 89.3        |              |
| > 70                 | 200      | 94.3       | 89.5        |              |

N.S. – not significant, PSA – prostate specific antigen
similar; but in G4 + 3, in patients treated with hormones, BRFS at 10 years was 90.9% and in those without hormones, 66.8% ($p < 0.01$) (9 relapses in 29 cases). When studying the cases with EBRT + BT, a difference was also observed only for Gleason score 4 + 3, with BRFS at 10 years going from 75.5% to 60% in the 5 cases who received BT only.

By clinical stage, the 10-year BRFS for T1c was 95% compared to 83% for T2a, 85.6% for T2b, and 84.7% for T2c. Moreover, a very significant difference ($p < 0.001$) between T1 and T2 (no difference between T2a, T2b and T2c) was observed (Fig. 3).

However, the initial PSA greater or lower than 10 ng/ml did not show differences with a 10-year BRFS of 91.6% with PSA < 10 vs. 88.9% with PSA between 10 and 20. The involvement of more than 50% biopsy cores did show a clear difference, 92% vs. 80% at 10 years ($p < 0.001$), and most relapses appeared in the first four years (Fig. 4).

Taking age into account, only 3 of 154 younger patients, up to 60 years of age relapsed, with a 10-year BRFS of 97.6% as compared with 89.4% in patients older than 60 years ($p < 0.013$).

Dosimetry at the end of the implant with exclusive BT achieved a $V_{100}$ of 97.3 ±1.9% (range, 84.7-99.9%), and $D_{90}$ of 169 ±8 Gy (range, 131-189 Gy) in the prostate. In cases with EBRT + BT, $V_{100}$ was 97 ±2% (range, 85-100%) and $D_{90}$ was 124 ±7 Gy (range, 102-137 Gy).

We reviewed 453 cases with PSA figures available at five years (excluding earlier failures or shorter follow-up), and the median PSA was 0.1 ng/ml (interquartile range, 0.04-0.2). Only one patient with PSA ≤ 0.2 suffered a biochemical recurrence.

Regarding toxicity, complications were recorded in 150 patients (21.2%): in the cases of exclusive BT (18.3%) and in those of EBRT + BT (33.3%). Urinary toxicity was observed as 18.7% (16.9% in BT alone vs. 26.1% in EBRT + BT), grade 2+ complications in 13.3%, and grade 3+ in 5.8%. Rectal or digestive toxicity was very low: 4% (2.5% in BT alone and 10.1% in EBRT + BT), grade 2+ complications in 1.6%, and grade 3+ in 0.1%. Table 3 describes urinary complications, and Table 4 shows digestive complications.

A comprehensive study investigating sexual function has not been carried out; it is difficult to assess in the long-term due to natural loss of function due to age.
Discussion

Radioactive seed brachytherapy of the prostate is an effective and widely used established treatment. In recent years, the number of implanted patients has been reduced due to greater access to robotic surgery as the first option for radical prostatectomy, and extensively used HDR-BT, available in more radiation oncology departments. PSA control results are good with all techniques in low-risk cases, due to slow growth of these carcinomas, which makes it possible to choose even active surveillance in very low-risk cases. In intermediate-risk cases, however, there are highly variable results, depending on the center and experience. It has been known for years that brachytherapy offers results that surpass EBRT or surgery [7], with recent meta-analysis confirming this theory [8]. Long-term results have been published, few with 10 years or more of follow-up, and a decrease in PSA control is always observed [9], achieving long-term PSA stability in 86% of cases treated with radioactive seeds [10]. Today, younger patients are treated thanks to early diagnosis by PSA screening. For this reason, it is essential to know the long-term results to offer all alternatives to patients. There are salvage treatments, but not all of them are effective, so the best primary treatment with a long expectation of control should be chosen, resulting with fewest possible complications.

In a well-known publication by Grimm et al. [11] comparing BRFS of different techniques, BT with radioactive seeds stands out as the one that offers the best long-term results at low-risk and alone, or in combination with EBRT at intermediate-risk. The results of the Seattle group [12, 13] at 10 years in low-risk group show 90% with seeds, and in the Mount Sinai Hospital of New York, 90% at 12 years [14]. Our study obtained 92.7% at 10 years, which indicates that it is undoubtedly a good treatment, even in young patients who are offered surgery more frequently.

In the intermediate-risk group, the Seattle group obtained 84% at 10 years with seeds, and 88% with combined EBRT + BT treatment. The Mount Sinai group reached 84% at 12 years in 973 patients [15]. In our center, we have achieved a 10-year BRFS of 88%, associating EBRT in 59% of the 226 intermediate-risk cases. The results of EBRT in hypofractionation studies with 20 fractions, such as CHHiP [16] or PROFIT [17], show that the results compared with standard EBRT are equal in intermediate-risk, so hypofractionation is considered recommended, with a 5-year BRFS ranging between 85% and 90.2%, but at 8 years, they drop to 74%. The NRG/RTOG 0126 study among 748 intermediate-risk patients treated with 79.2 Gy reported an 8-year control of 80% [18]. A Spanish multicenter RECAP study with 1,294 patients had a BRFS of 88.9% at 5 years, but decreased to 71.4% at
10 years [19]. All these indicate that long-term results worsen when using only EBRT with or without hormonal therapy; therefore, maintaining 88% control at 10 years in the intermediate-risk group of our study was highly significant. Two studies comparing seeds as boost versus exclusive external RT (ASCENDE-RT [20]) and with EBRT or surgery [21], clearly show the advantage of using seed BT. In our study, we verified that there are risk factors that reduce control, especially Gleason score 4 + 3 and > 50% biopsy cores positive. The appearance of long-term biochemical relapses in these cases indicates a more aggressive disease and requires a different approach. It is necessary to change from exclusive BT to a triple treatment combined with EBRT of the prostate and seminal vesicles, BT boost with seeds, and ADT for 6 months [22, 23]. The use of hormonal therapy was not significant in our study, except for unfavorable cases. It must be taken into account that there are low-risk cases who received ADT for 3 months to reduce prostate volume. A recent meta-analysis recommends that approach in such as in our study unfavorable cases [24]. The 2018 NCCN recommendations already propose a new classification that divides intermediate-risk cases into favorable and unfavorable, and their management should be different [25, 26]. This group of patients will be the subject of more detailed analysis in another publication.

Age is an important factor when choosing primary treatment, since there is a tendency to recommend surgery as the first option in young patients, due to long life expectancy; although BT appears to offer at least similar results [27]. In our study, patients up to 60 years of age had better control than older patients (97.6% at 10 years vs. 89.4%), which makes the option of BT with radioactive seeds clearly recommended, allowing better preservation of erectile function [28]. Long-term BRFS rates of 96.98.9% have been published in men aged 55 or younger [29, 30].

Regarding toxicity, we found that the association of EBRT and seeds supposes a greater risk of urological (from 16.9% to 26.1%) and rectal complications (from 2.5% to 10.1%). Generally, the use of external RT increases the risk of digestive toxicity [31]. Even so, urological G3 toxicity occurs only in 5.8% and rectal G3 toxicity in one case, fewer than the data published in the ASCENDE-RT study (only 6% of toxicity was persistent) [32].

The technique used is important, since a real-time system and placement of fixed intraoperatively built custom-linked seeds allows for better dosimetry and lower doses to organs at risk. We achieve excellent dosimetry, with mean V100 of 97% and mean D2cc of 169 Gy with exclusive BT, and 124 Gy with combined treatment. This can be one of the reasons why the results from multiple hospitals are not so favorable. A collection of 582 intermediate-risk cases treated with exclusive seed brachytherapy in eleven Italian hospitals obtained an 8-year BRFS rate of 78.4% [33], 10% lower than in our study. It is essential to use a good implant technique to recommend BT as the first option over EBRT or prostatectomy [5, 34].

Treatment of low- and intermediate-risk patients with two-session high-dose-rate BT or 5-session SBRT is promising, but we do not yet achieve 10-year results [35]. We are aware that biochemical relapses can appear in long-term, if a PSA level at 4-5 years below 0.2 ng/ml is not reached, what is considered a biochemical definition of cure [36]. Moreover, an analysis of 3,502 patients showed that LDR-BT led to lower nadir PSAs, with longer continued decay compared to SBRT and HDR-BT [37]. Low-dose-rate brachytherapy is in decline, but with the results obtained in our experience with the real-time technique and custom-linked seed system, the implantation of 125I seeds in a single-day still remains the most attractive option to achieve long-term control.

Conclusions

Brachytherapy with 125I seeds is a very effective long-term treatment for low- and intermediate-risk carcinoma of the prostate. In 706 patients, we obtained a 10-year BRFS of 92.7% in low-risk and 88% in intermediate-risk patients. In cases with Gleason score 4 + 3 or > 50% biopsy cores positive, there are more relapses, which coincides with a recommendation to consider them as an unfavorable intermediate group, and we recommend giving triple treatment with EBRT + BT with additional ADT for 6 months. The real-time technique with intra-operatively built custom-linked seeds allows implants with high quality dosimetry, and makes it possible to achieve excellent biochemical control, which is maintained in the long-term. Toxicity is limited in cases with combined treatment and very low with exclusive BT. Based on these results, BT with 125I seeds should be offered to selected patients as one of the main therapeutic options, especially to young patients.

Acknowledgments

We thank PALEX Medical S.A. for the funds to collect patient data, Irene Monleon for her dedication to this work, and Haydeé Gutierrez for her support.

Disclosure

The authors report no conflict of interest.

References

1. National Comprehensive Cancer Network: Prostate Cancer Version 3.2016. National Comprehensive Cancer Network 2016.
2. D’Amico AV, Whittington R, Malkowicz SB et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-974.
3. Preissler F, Cooperberg MR, Crook J et al. Intermediate-risk prostate cancer: stratification and management. Eur Urol Oncol 2020; 3: 270-278.
4. Okazaki E, Kuratsukuri K, Nishikawa T et al. Comparison of post-implant dosimetrics between intraoperatively built custom-linked seeds and loose seeds by sector analysis at 24 hours and 1 month for localized prostate cancer. J Contemp Brachytherapy 2020; 12: 317-326.
5. Guinot JL, Ricós JV, Tortajada MI et al. Comparison of permanent 125-I seeds implants with two different techniques in 500 cases of prostate cancer. J Contemp Brachytherapy 2015; 7: 258-264.
6. National Institutes of Health. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0 11.27.2017.
7. Vassil AD, Murphy ES, Reddy CA et al. Five-year biochemical and clinical free survival for intermediate-risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. Urology 2010; 76: 1251-1257.
8. Kee DLC, Gal J, Falk AT et al. Brachytherapy versus external beam radiotherapy boost for prostate cancer: Systematic review with meta-analysis of randomized trials. Cancer Treat Rev 2018; 70: 265-271.
9. Hinnen KA, Batternmann JJ, van Roermund JG et al. Long-term biochemical and survival outcome of 921 patients treated with 125 permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2010; 76: 1433-1438.
10. Tetreault-Laflamme A, Crook J, Hamm J et al. Long-term prostate specific antigen stability and predictive factors of failure after permanent seed prostate brachytherapy. J Urol 2018; 199: 120-125.
11. Grimm P, Billiot I, Bostwick D et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. BJU Int 2012; 109 Suppl 1: 22-29.
12. Sylvester JE, Grimm PD, Blasko JC et al. 15-year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy, Seattle experience. Int J Radiat Oncol Biol Phys 2007; 67: 57-64.
13. Sylvester JE, Grimm PD, Wong J et al. Fifteen-year biochemical relapse-free survival, cause-specific survival, and overall survival following I(125) prostate brachytherapy in clinically localized prostate cancer: Seattle experience. Int J Radiat Oncol Biol Phys 2011; 81: 376-381.
14. Lazarev S, Thompson MR, Stone NN, Stock RG. Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up. BJU Int 2018; 121: 781-790.
15. Marshall RA, Buckstein M, Stone NN, Stock R. Treatment outcomes and morbidity following definitive brachytherapy with or without external beam radiation for the treatment of localized prostate cancer: 20-year experience at Mount Sinai Medical Center. Urol Oncol 2014; 32: 38.e1-7.
16. Dearnaley D, Syndikus I, M mossop H et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer. 5-year outcomes of the randomised, non-inferiority, phase 3 CHHIP trial. Lancet Oncol 2016; 17: 1047-1060.
17. Catton CN, Lukka H, Gu CS et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol 2017; 35: 1884-1890.
18. Michalski JM, Moughan J, Purdy J et al. Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer. The NRG Oncology RTOG 0426 Randomized Clinical Trial. JAMA Oncol 2018; 4: e180039.
19. Hervás A, Pastor J, González C et al. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database. Clin Transl Oncol 2019; 21: 900-909.
20. Morris WJ, Tyldesley S, Rodda S et al. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017; 98: 275-285.
21. Goy BW, Burchette R, Soper MS et al. Ten-year treatment outcomes of radical prostatectomy vs external beam radiation therapy vs brachytherapy for 1503 patients with intermediate-risk prostate cancer. Urology 2020; 136: 180-189.
22. Keyes M, Merrick G, Frank SJ et al. American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapy – a systematic literature review. Brachytherapy 2017; 16: 245-265.
23. Villalba SR, Denia PM, Perez-Calatayud MJ et al. Low-/high-dose rate brachytherapy boost in patients with intermediate-risk prostate cancer treated with radiotherapy: long-term results from a single institution team experience. J Contemp Brachytherapy 2021; 13: 135-144.
24. Jackson WC, Hartman HE, Hess RT et al. Addition of androgen-deprivation therapy or brachytherapy boost to external beam radiotherapy for localized prostate cancer: a network meta-analysis of randomized trials. J Clin Oncol 2020; 38: 3024-3031.
25. Zumsteg ZS, Zelefsky MJ, Woo KM et al. Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer. BJU Int 2017; 120 (58): E87-E95.
26. Xie M, Gao XS, Ma MW et al. Population-based comparison of different risk stratification systems among prostate cancer patients. Front Oncol 2021; 11: 646073.
27. Ashamalla H, Guirguis A, McCool K et al. Brachytherapy improves outcomes in young men (≤60 years) with prostate cancer: A SEER analysis. Brachytherapy 2017; 16: 323-329.
28. Zhang P, Qian B, Shi J, Xiao Y. Radical prostatectomy versus brachytherapy for clinically localized prostate cancer on oncological and functional outcomes: a meta-analysis. Transl Androl Urol 2020; 9: 332-343.
29. Gómez-Itrurriaga Piña A, Crook J, Borg J et al. Median 5-year follow-up of 125 iodine brachytherapy as monotherapy in men aged < or = 55 years with favorable prostate cancer. Urology 2010; 75: 1412-1416.
30. Merrick GS, Wallner KE, Butler WM et al. Brachytherapy in men aged < or = 54 years with clinically localized prostate cancer. BJU Int 2006; 98: 324-328.
31. Moll M, Paschen C, Zaharie A et al. Treatment of low-risk prostate cancer: a retrospective study with 477 patients comparing external beam radiotherapy and I-125 seeds brachytherapy in terms of biochemical control and late side effects. Strahlenther Onkol 2021; 197: 118-123.
32. Rodda S, Tyldesley S, Morris WJ et al. ASCENDE-RT: an analysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017; 98: 286-295.
33. Fellin G, Mirri MA, Santoro L et al. Low dose rate brachytherapy (LDR-BT) as monotherapy for early stage prostate cancer in Italy: practice and outcome analysis in a series of 2237 patients from 11 institutions. Br J Radiol 2016; 89: 20150981.
34. Pons-Llanas O, Collado-Ballesteros E, Roldan-Ortega S et al. Impact of real-time, dose-escalated permanent seed implant brachytherapy in intermediate-risk prostate cancer. Rep Pract Oncol Radiother 2020; 25: 463-469.
35. Corkum MT, Achard V, Morton G, Zilli T. Ultrahypofractionated radiotherapy for localised prostate cancer: how far can we go? Clin Oncol (R Coll Radiol) 2022; 34: 340-349.
36. Crook JM, Tang C, Thames H et al. A biochemical definition of cure after brachytherapy for prostate cancer. Radiother Oncol 2020; 149: 641-648.
37. Levin-Epstein R, Cook RR, Wong JK et al. Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. Radiother Oncol 2020; 151: 26-32.